A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects

This will be a single-site, single-dose, randomized, open-label, two-treatment, two-sequence, four-period replicated crossover study in healthy adult subjects. The study will comprise a screening period, four treatment periods with a 7-day washout between dosing in each period, and a safety follow-up visit.